Next-Generation Vaccine for Necrotic Enteritis Prevention in Poultry

A novel vaccine system combining immunogenic and non-toxic components of alpha-toxin and NetB, produced in microorganisms and administered orally or via injection, providing enhanced protection against necrotic enteritis in poultry.

The original patent described a vaccine comprising an antigenic protein with PlcC and NetB protein units, but it had limitations in terms of administration methods and efficacy. The new inventive concept addresses these limitations by introducing a fusion protein combining immunogenic and non-toxic components of alpha-toxin and NetB, produced in microorganisms and administered orally or via injection, providing enhanced protection against necrotic enteritis in poultry.

The new inventive concept comprises a vaccine system consisting of a fusion protein combining immunogenic and non-toxic components of alpha-toxin and NetB, produced in microorganisms. The fusion protein is administered orally or via injection to poultry, providing enhanced protection against necrotic enteritis. The oral administration method allows for easy and cost-effective vaccination, while the injection method provides an alternative for more targeted administration. The fusion protein is designed to elicit a strong immune response, providing long-term protection against necrotic enteritis.

The new claims introduce a novel fusion protein combining immunogenic and non-toxic components of alpha-toxin and NetB, produced in microorganisms, which is not obvious from the original patent. The combination of oral and injection administration methods provides a new and non-obvious solution for necrotic enteritis prevention in poultry.

Alternative embodiments of the inventive concept include using different microorganisms for production, varying the ratio of alpha-toxin and NetB components, and incorporating adjuvants to enhance the immune response. Variations of the administration method, such as nasal sprays or feed supplements, could also be explored.

The new inventive concept has significant commercial potential in the poultry industry, where necrotic enteritis is a major concern. The vaccine system could be marketed as a more effective and convenient solution for poultry farmers, providing a competitive advantage in the market.